Opko Health to sell more assets to LabCorp

Labcorp to buy Opko unit’s cancer test assets for up to $225M
Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth testing areas.
Labcorp to acquire select oncology testing assets for up to $225M
The independent laboratory company has entered an agreement to acquire BioReference Health's oncology diagnostic services.
Opko Health to sell more assets to Labcorp for $225 million
The sale comes after the Miami company agreed to pay $704,349 to settle allegations that it billed the federal government for unnecessary blood tests.
Labcorp to acquire certain assets of Opko Health’s BioReference Health
Labcorp (LH) and OPKO Health (OPK) announced earlier on Tuesday that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Labcorp to Buy Some OPKO BioReference Assets for Up to $225 Million
Labcorp Holdings has signed a deal to buy certain assets of OPKO Health's BioReference Health unit for up to $225 million. Labcorp on Tuesday said it will pay $192.5 million at closing for BioReference's laboratory testing businesses, which is focused on oncology and oncology-related clinical testing services across the U.S.
Labcorp Acquiring BioReference Health Oncology Testing Assets for $225M
The deal is part of BioReference's ongoing effort to streamline its business to achieve profitability and follows the sale last year of clinical laboratory assets to Labcorp.
Labcorp pays $225 million for BioReference's oncology testing lines in latest acquisition
Labcorp continues string of acquisitions with a deal adding BioReference oncology services in $225 million deal. Burlington-based Labcorp is investing almost a quarter of a billion dollars to add oncology testing services in its most recent acquisition.
Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors
This was the stock's sixth consecutive day of losses.
Supreme Court may limit class certification through Article III standing requirement
Daniel B. Levin, Bethany Kristovich and Colin A. Devine of Munger, Tolles & Olson LLP discuss a question before the Supreme ...
Zacks Investment Research on MSN6d
Should Labcorp Stock Stay in Your Portfolio Right Now?
Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.
Hosted on MSN24d
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
Labcorp Holdings Inc. LH, or Labcorp, is positioning itself for sustained growth with a series of strategic acquisitions and partnerships. With a growing emphasis on cell and gene therapy ...
Truist Financial Remains a Buy on Labcorp Holdings (LH)
In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Labcorp Holdings (LH – Research Report), with a ...